Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.59 |
| ▸ | WNT3A | P56704 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314527 | 1.00 | MEN1 (0.70) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL10568457 | 0.89 | MEN1 (0.64) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL12378894 | 0.89 | MEN1 (0.68) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL25966580 | 0.88 | HSD17B2 (0.68) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL7380780 | 0.87 | MAPT (0.61) | MEN1KMT2AALDH1A1MAPTTSHR | |
| SCHEMBL15657696 | 0.87 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL3189296 | 0.87 | ALDH1A1 (0.61) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL31493234 | 0.87 | MEN1 (0.61) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL15657764 | 0.87 | MEN1 (0.65) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL11705162 | 0.86 | CTNNB1 (0.70) | MEN1KMT2AALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087561-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | SIKA TECHNOLOGY AG (CH) | 2026-04-30 | — | — | WO | claimed |
| EP-4733284-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | Sika Technology AG (CH) | 2026-04-29 | — | — | EP | claimed |
| EP-4063422-A1 | 1,3-DICARBONYL COMPOUNDS AS RETARDING ADDITIVES FOR UCRETE SYSTEMS | Construction Research & Technology GmbH (DE) | 2022-09-28 | — | — | EP | claimed |
| CN-109369592-A | A kind of synthetic method of sweet orange flavones | 陕西嘉禾生物科技股份有限公司 | 2019-02-22 | — | — | CN | claimed |
| US-9422583-B2 | Stereospecific carbonyl reductases | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-23 | — | — | US | claimed |
| US-20150167032-A1 | STEREOSPECIFIC CARBONYL REDUCTASES | JIANGNAN UNIVERSITY (CN) | 2015-06-18 | — | — | US | claimed |
| CN-102482649-B | Stereospecific carbonyl reductases | UNIV RUTGERS | 2014-09-03 | — | — | CN | claimed |
| US-20120270285-A1 | STEREOSPECIFIC CARBONYL REDUCTASES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-10-25 | — | — | US | claimed |
| CN-102482649-A | Stereospecific carbonyl reductases | UNIV RUTGERS | 2012-05-30 | — | — | CN | claimed |
| WO-2010151593-A1 | STEROSPECIFIC CARBONYL REDUCTASES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-12-29 | — | — | WO | claimed |
| CN-1297552-C | Process for synthesizing luteolin | NANJING RALLY BIOCHEMICAL CO L (CN) | 2007-01-31 | — | — | CN | claimed |
| WO-2026087561-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | SIKA TECHNOLOGY AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4733284-A1 | RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS | Sika Technology AG (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-11964985-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | The Regents of the University of Colorado, a body corporate. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| EP-0101330-B1 | 2-QUINOLONE DERIVATIVES | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1988-08-24 | — | — | EP | disclosed |
| US-4727073-A | CEREBOVASCULAR DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-23 | — | — | US | disclosed |
| EP-0177287-A2 | Pyrimidine derivatives, processes for preparation thereof and composition of the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-09 | — | — | EP | disclosed |
| US-4526894-A | Antiinflammatory agents | NIPPON SHINYAKU CO. LTD. (JP) | 1985-07-02 | — | — | US | disclosed |
| EP-0101330-A2 | 2-Quinolone derivatives | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | MEN1 3423/4885KMT2A 1582/4885ALDH1A1 1088/4885 |
| US-11964985-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, IQGAP1 | MEN1 1827/4885KMT2A 2921/4885ALDH1A1 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.